|
Found 42 result(s) FROM 1963 pages containing the term 'Romanus sign'.
Tuesday Mar 23, 2010
President Obama Signs Landmark Health Care Bill Into Law
The historic bill is the most sweeping social legislation to be enacted in decades, and will overhaul the nation's $2.5 trillion health care system...
Wednesday Aug 05, 2009
Lupus with Leucopenia, Anemia Signals Risk of Leukemia
Lupus patients with persistent leucopenia or anemia may be at risk for myeloid leukemia...
Thursday Nov 20, 2008
BioLineRx, Yissum Sign a Licensing Agreement for the Development of an Anti-Leptin Compound for the Treatment of IBD
BioLineRx signed an exclusive license agreement with Yissum Ltd to develop and commercialize BL-5040, an antagonist of leptin with anti-inflammatory properties for the treatment of inflammatory bowel disease (IBD)...
Friday Nov 07, 2008
Studies Confirm, Extend Uses of MRI in Spondyloarthropathies
Severe romanus lesions in patients with back pain who are younger than 51 are very specific for spondyloarthropathy, and an MRI of just the sacroiliac joint is generally enough to diagnose nonradiographic axial SpA, regardless of the location of the back pain...
Wednesday Aug 06, 2008
NeoStrata Reports Novel Nonprescription Coal Tar Solution Provides Significant Benefits Versus Calcipotriol for Moderate Psoriasis
Findings from an ongoing 12-week study demonstrate benefits of a novel, nonprescription topically applied LCD (coal tar) solution (Psorent™) versus calcipotriol cream (Dovonex®) in treatment of moderate plaque psoriasis...
Monday Aug 04, 2008
Manhattan Pharmaceuticals Reports Phase IIa Results of PTH (1-34) for Psoriasis; Cream is Well Tolerated but No Significant Improvement in Treated Lesions Compared With Vehicle
Data from from the phase IIa clinical study of a reformulated topical PTH (1-34) for the treatment of psoriasis did not demonstrate a statistically significant improvement in the overall disease severity of treatment lesions or signs and symptoms of psoriasis compared with vehicle gel...
Thursday May 22, 2008
Bone Pain Can Be a Sign of Myeloma
Patients who report bone pain should be checked for myeloma, a treatable form of bone marrow cancer
Thursday May 01, 2008
La Jolla Pharmaceutical Reports Positive 12-Month Interim Antibody Data From Phase III Study of Riquent® for SLE; Significant, Sustained Reductions Observed in Antibodies to dsDNA
Analyses of data in the first 125 randomized patients indicate that for all patients treated with Riquent® compared with placebo, there were significantly greater reductions in antibodies to double-stranded (ds) DNA...
Monday Feb 04, 2008
Amgen, Wyeth Report Enbrel® (etanercept) Significantly Reduced Levels of CRP, a Marker of Inflammation, in Patients with Moderate-to-Severe Plaque Psoriasis
Amgen Inc and Wyeth Pharmaceuticals announced findings from a retrospective analysis demonstrating that Enbrel® (etanercept), a fully human soluble TNF receptor, reduced C-reactive protein (CRP) in patients with moderate-to-severe plaque psoriasis...
Tuesday Jan 22, 2008
Dermal Mucin in Alopecia Areata - Tell Tale Sign or Incidental Finding?
Dermal deposition of mucin may serve as a clue for diagnosing lupus in alopecia patients…
Tuesday Jan 15, 2008
Three More Cases of Significant Neutropenia Lead to Recommendation for Routine CBC Monitoring
Three more cases of significant neutropenia in rheumatoid arthritis (RA) and psoriatic arthritis patients treated with etanercept lead to a recommendation for regular monitoring of complete blood counts (CBC)...
Tuesday Dec 18, 2007
Rigel's Oral Syk Kinase Inhibitor, R788 (tamatinib fosdium), Achieves Statistically Significant ACR-20, -50, -70 in Phase II RA Clinical Study; Achieves Effect As Early As 1 Week
Rigel Pharmaceuticals, Inc announced that its oral syk kinase inhibitor, R788 (tamatinib fosdium), has demonstrated statistically significant results in treating rheumatoid arthritis patients in a recently completed phase II clinical trial...
Monday Dec 03, 2007
Targeted Genetics Announces That US FDA Removed Hold on Phase I/II Clinical Trial of tgAAC94 for Inflammatory Arthritis; Phase II Clinical Trial Protocol Design Underway
Targeted Genetics Corp announced that the US FDA removed the hold on the company's phase I/II clinical trial of tgACC94 for inflammatory arthritis, following the agency's review of the safety data thus far on all 127 subjects and all data from a fatal serious adverse event, which led to the death of a patient...
Thursday Nov 29, 2007
Osiris Announces Clinically and Statistically Significant 1-Year Data From Phase I/II Trial of Chondrogenâ„¢; OA Knee Patients Receive Single Injection of Adult Stem Cells Into Knee
Osiris Therapeutics, Inc, a leading stem cell therapeutic company, announced positive 1-year interim results in the evaluation of Chondrogenâ„¢, a preparation of mesenchymal stem cells obtained from the bone marrow of healthy adult donors and formulated for direct injection into the knee...
Thursday Nov 08, 2007
Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Improved Articular, Skin, and Nail Manifestations in Patients With Psoriatic Arthritis in Phase III Study; Met Primary and Major Secondary Endpoints
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that patients with active psoriatic arthritis (PsA) receiving monthly subcutaneous injections of golimumab experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest phase III biologic study (GO-REVEAL trial) in PsA subjects...
Thursday Nov 08, 2007
Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of AS in Phase III Study; Monthly Treatment Yielded Marked Improvements in Physical Function
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that more than half of patients receiving monthly subcutaneous injections of golimumab 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis (AS), according to the phase III study (GO-RAISE trial) results...
Thursday Oct 25, 2007
Systematic Review: Few Signs of Tai Chi Efficacy in RA
Tai chi exercise is often recommended for patients with arthritis, including RA, but a systematic review finds little evidence that it is effective...
Wednesday Oct 03, 2007
First Case Reported of Lupus Erythematosus Tumidus Induced by Sex Reassignment Surgery
Environmental triggers contribute to lupus pathogenesis, and the hormone regimens used in male-to-female sex reassignment can induce lupus-like symptoms...
Wednesday Sep 12, 2007
Trubion's Preliminary Analysis of Phase IIb Results With Immunotherapeutic TRU-015 Show Improvements in RA Signs and Symptoms Compared With Placebo
Trubion Pharmaceuticals, Inc, a biopharmaceutical company creating product candidates to treat autoimmune disease and cancer, announced preliminary analysis of results from a phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial of its TRU-015 immunotherapeutic product candidate for rheumatoid arthritis (RA)...
Friday May 18, 2007
Little Benefit Found for Amitriptyline in JIA, But New Research Design May Speed Clinical Trials
Amitriptyline is ineffective for JIA pain, but multiple serial N-of-1 trials plus Bayesian meta-analysis can be used with low patient numbers to weed out treatments that don't merit study in large clinical trials...
Monday May 07, 2007
Novartis' Once-Yearly ReclastR Significantly Reduces Bone Fractures in Women With Postmenopausal Osteoporosis
Novartis Pharmaceuticals Corp announced that its once-yearly treatment of ReclastR (zoledronic acid) significantly reduces the incidence of all types of osteoporotic bone fractures in women with postmenopausal osteoporosis...
Wednesday Mar 21, 2007
BioMimetic Receives Orphan Drug Designation for rhPDGF-BB Treatment of Osteonecrosis of the Jaw
BioMimetic Therapeutics, Inc, an emerging leader in developing and commercializing bioactive drug-device combination drugs to heal musculoskeletal injuries and disease, including periodontal, orthopaedic, spine and sports injuries, announced that it has received orphan drug designation from the US FDA for its protein therapeutic, recombinant human platelet-derived growth factor (rhPDGF-BB)...
Wednesday Mar 07, 2007
Evotec and Interprotein Sign Collaboration Agreement to Develop Small Molecule Interleukin-6 Inhibitors to Treat Inflammatory Diseases
Evotec AG, a leader in the discovery and development of small molecule drugs, and Interprotein Corporation, a developer of orally bioavailable small molecule drugs that modulate protein-protein interactions, announced that they have signed a collaboration agreement on Interprotein's interleukin-6 (IL-6) inhibitors program for the development of novel, orally active drugs for the treatment of inflammatory diseases...
Tuesday Feb 27, 2007
UCB Reports Significant Reduction in Joint Damage From Phase III Results With Cimzia in Rheumatoid Arthritis; Fc Region Present in Conventional Anti-TNFs Is Not Required for Activity
UCB, a global biopharmaceutical company, announced results of an international, multicenter, placebo-controlled phase III study (RAPID 1) involving nearly 1000 patients that evaluated the investigational agent Cimziaâ„¢ (certolizumab pegol)...
Tuesday Feb 13, 2007
Rheumatologists Advised to Be Alert for Signs of Serum Sickness in Rituximab-Treated Patients
The first case of rituximab-induced serum sickness in a patient without an underlying autoimmune disorder suggests that this problem might be under-recognized in RA and SLE patients...
Thursday Feb 08, 2007
More Patient Input on Design Needed If RA Patients Are Actually to Wear Therapeutic Shoes
More attention to shape and design of shoes for feet of RA patients...
Thursday Jan 04, 2007
FivePrime Signs Collaborative Research and License Deal With Centocor to Discover Therapeutics to Treat OA and Other Diseases
FivePrime Therapeutics, Inc, a privately held protein therapeutics discovery and development company, announced the signing of a worldwide collaborative research and license agreement with Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, to discover therapeutic products to treat osteoarthritis (OA) and pulmonary fibrosis.
Tuesday Nov 07, 2006
Ablynx, Wyeth Sign Exclusive Research and License Agreement for Nanobodies® Directed at TNF-α and Its Receptors
Ablynx, a biopharmaceutical company engaged in the discovery and development of a novel class of therapeutic proteins based on single-domain antibody fragments (Nanobodies®) announced that they have entered into a research collaboration and exclusive worldwide license agreement with Wyeth Pharmaceuticals (a division of Wyeth) to discover, develop, and commercialize Nanobodies directed at TNF-α and its receptors, targeting diseases in multiple therapeutic areas.
Friday Oct 06, 2006
OA May Be A Sign of Faster Biological Aging
Signs of accelerated biological aging found in patients with OA...
Tuesday Sep 19, 2006
Predix (now known as EPIX) Signs Exclusive Collaboration and License Agreement with Amgen, Potentially Worth Over $307.5 Million, for the Development of S1P1 Modulators for Treatment of Autoimmune Diseases; Predix Completes Merger with EPIX
Predix Pharmaceuticals Holdings, Inc. announced an exclusive collaboration and licensing deal with Amgen to develop Predix's existing preclinical and new, orally available S1P1 modulators for autoimmune diseases.
Monday Sep 18, 2006
Novartis' Once-Yearly Reclast Investigational Infusion Osteoporosis Treatment Significantly Cuts Risk of Spine and Hip Fractures in Postmenopausal Women
Novartis Pharmaceuticals Corporation announced that phase III data presented at the 28th Annual meeting of the American Society for Bone and Mineral Research (ASBMR), September 15–19, 2006, in Philadelphia, Pa, demonstrated that its investigational, once-yearly bisphosphonate 15-minute infusion treatment, Reclast® (zoledronic acid) 5 mg, was highly effective at reducing the incidence of bone fracture in women with postmenopausal osteoporosis across the most common fracture sites—hip, spine, and nonspine (with the exception of face, fingers, and toes)—with sustained effect over 3 years.
Monday Jun 12, 2006
Regeneron's IL-1 Trap Receives Fast-Track Designation From US FDA for CIAS1-Associated Periodic Syndromes (CAPS)
Regeneron's IL-1 Trap has received fast-track designation from the US FDA for CIAS1-Associated Periodic Syndromes (CAPS), a family of rare autoinflammatory diseases...
Saturday Jun 10, 2006
Regeneron's IL-1 Trap Receives Fast-Track Designation from US FDA for CIAS1-Associated Periodic Syndromes (CAPS), a family of rare autoinflammatory diseases
Regeneron's IL-1 Trap Receives Fast-Track Designation from US FDA for CIAS1-Associated Periodic Syndromes (CAPS), a family of rare autoinflammatory diseases
Friday Jun 09, 2006
Cytopia Signs Exclusive License and Collaboration Agreement With Novartis for JAK3 Kinase Inhibitors in Autoimmune Diseases and Transplant Rejection
Cytopia Ltd announced the execution of a worldwide license and R&D collaboration agreement with Novartis to develop orally active, small-molecule therapeutics targeting JAK3 kinase...
Friday Jun 09, 2006
Aspreva and Roche Granted Orphan Drug Designation for Mycophenolate Mofetil (Cellcept®) in Pemphigus Vulgaris
Aspreva Pharmaceuticals Corp announced that the US FDA has granted Orphan Drug designation for mycophenolate mofetil...
Friday Apr 14, 2006
Centocor's Remicade® Designated for Priority Review by FDA for Pediatric Crohn's Disease
Centocor, Inc, of Horsham, Pennsylvania, announced that the supplemental Biologics License Application (sBLA) for Remicade® (infliximab)...
Thursday Mar 02, 2006
Simple Formula Helps Doctors Determine When Height Loss Signifies Osteoporosis
Historical height loss can help predict the likelihood of vertebral fractures and the need for spine radiographs... Siminoski K, et al. Osteoporos Int. 2006;17:290-296.
Thursday Feb 23, 2006
G2 Inflammation Pty Ltd Signs Deal With Novo Nordisk for Anti-C5a Receptor Antibody for the Treatment of RA and Other Inflammation-Mediated Diseases
G2 Inflammation Pty Ltd (G2I) announced a research, development, and licensing agreement with the Danish healthcare company Novo Nordisk to advance G2's Neutrazumab...
Monday Nov 07, 2005
Positive Phase III Results for Remicade® in Pediatric Crohn's Disease Drives Fast Track Designation for Indication
Centocor, Inc (Horsham, Pa.), announced at the 18th Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...
Wednesday Jan 19, 2005
Next Generation of Antibody-Based Designer Biologics in Development
Trubion announces first Phase I study of small modular immunopharmaceutical SMIP technology in rheumatoid arthritis…
Wednesday Oct 13, 2004
Significant Advantages Favor Alendronate for Bone Protection
A new trial comparing 2 bisphosphonate formulations finds greater benefits with alendronate vs risedronate and no significant differences between the 2 in reported adverse events, including those associated with upper GI tolerability …Rosen C, et al. J Bone Miner Metab. 2004;19(suppl 1):S94. Abstract F412.
Thursday Sep 30, 2004
Pulsed IV Methylprednisolone Produces Significant Bone Loss, Short-Term Study Shows
Conventional wisdom holds that pulsed IV corticosteroids reduce the risk of bone loss. New findings show that even this treatment schedule is associated with significant reductions in bone mineral density...Haugeberg G et al. Ann Rheum Dis. 2004;63:940-944.
|
